Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|January 15, 2015
Classifying and Predicting Response in NETs
Author(s)Pamela L. Kunz, MD
Pamela L. Kunz, MD, discusses classifying neuroendocrine tumors (NETs) and the potential to predict response.
Advertisement
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses classifying neuroendocrine tumors (NETs) and the potential to predict response.
Advertisement
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5